{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '47', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'In adult participants with treatment-na\u00efve, metastatic NSCLC expressing PD-L1 (TPS >1%):', 'Objectives', 'Enppoints', 'Primary', 'Objective: To compare progression-free', 'PFS, defined as the time from', 'survival (PFS) as assessed by blinded', 'randomization to the first documented', 'independent central review (BICR)', 'progressive disease (PD) or death due to', 'according to Response Evaluation', 'any cause, whichever occurs first*', 'Criteria in Solid Tumors, version 1.1', '(RECIST 1.1), adjusted to follow a', 'maximum of 10 target lesions and a', 'maximum of 5 target lesions per organ,', 'for the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab +', 'matching placebo', '- Hypothesis (H1): The combination of', 'pembrolizumab + lenvatinib has', 'superior PFS per RECIST 1.1, as', 'defined in Section 4.2.1.1.1, based on', 'BICR', 'Objective: To compare overall survival', 'OS, defined as the time from', '(OS) for the combinations of', 'randomization to death due to any cause*', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Hypothesis (H2): The combination of', 'pembrolizumab + lenvatinib has', 'superior os', 'Secondary', 'Objective: To compare objective response', 'Objective response (OR), defined as a', 'rate (ORR) as assessed by BICR', 'confirmed complete response (CR) or', 'according to RECIST 1.1, as defined in', 'partial response (PR)', 'Section 4.2.1.1.1, for the combinations of', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Hypothesis (H3): The combination of', 'pembrolizumab + lenvatinib has', 'superior ORR per RECIST 1.1, as', 'defined in Section 4.2.1.1.1, based on', 'BICR', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '48', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Objectives', 'Enppoints', 'Objective: To evaluate the safety and', 'Adverse events (AEs) and study', 'tolerability for the combinations of', 'intervention discontinuation due to AEs', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', 'Objective: To compare the mean change', 'Change from baseline for the following', 'from baseline in the global health', 'patient-reported outcomes (PROs)', 'status/quality of life (QoL), cough, chest', 'scales/items: global health status/QoL', 'pain, dyspnea, and physical functioning', '(EORTO QLQ-C30 items 29 and 30),', 'for the combinations of pembrolizumab +', 'cough (EORTC QLQ-LC13 item 31),', 'lenvatinib versus pembrolizumab +', 'chest pain (EORTC QLQ-LC13 item 40),', 'matching placebo', 'dyspnea (EORTO QLQ-C30 item 8), and', 'physical functioning (EORTC QLQ-C30', 'items 1-5)', 'Objective: To compare the time to true', 'TTD, defined as the time from baseline', 'deterioration (TTD) in global health', 'to the first onset of a 10-point', 'status/QoL, cough, chest pain, dyspnea,', 'deterioration from baseline with', 'and physical functioning for the', 'confirmation by the subsequent visit of a', 'combinations of pembrolizumab +', '>10-point deterioration from baseline in', 'lenvatinib versus pembrolizumab +', 'global health status/QoL (EORTC', 'matching placebo', 'QLQ-C30 items 29 and 30), cough', '(EORTC QLQ-LC13 item 31), chest pain', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTO QLQ-C30 items', '1-5)', 'TTD in the composite endpoint', '(combination of cough [QLQ-LC13 item', '31], chest pain [QLQ-LC13 item 40], or', 'dyspnea [QLQ-C30 item 8]) defined as', 'the time to first onset of a 10-point', 'deterioration from baseline in any one of', '3 scale items with confirmation by the', 'subsequent visit of a 10-point', 'deterioration from baseline in the same', 'scale as the first onset', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}